On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
Mahaz Kayani(University College Hospital), Carmel Pezaro(Royal Marsden NHS Foundation Trust), Hilary Glen(Beatson West of Scotland Cancer Centre), Ashwin Sachdeva(University of Manchester), Mark Beresford(Royal United Hospital Bath NHS Trust), Cathryn Woodward, Anjali Zarkar(Cancer Research UK), Mau-Don Phan, Zafar Malik(Clatterbridge Cancer Centre NHS Foundation Trust), Claire Amos(MRC Clinical Trials Unit at UCL), Sangeeta Paisey(Hampshire Hospitals NHS Foundation Trust), Sarah Howlett(University College Hospital), Michael Brown(University of Manchester), Elin Jones, Anna Tran, Katherine Hyde, Krishna Narahari, Azman Ibrahim, Thiagarajan Sreenivasan(United Lincolnshire Hospitals NHS Trust), Minal Padden-Modi(Royal Marsden NHS Foundation Trust), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Jane Worlding(University Hospitals Coventry and Warwickshire NHS Trust), Richard Shaffer(Bupa Cromwell Hospital), Sue Brock, Denise Sheehan(Royal Devon and Exeter Hospital), D. Muthukumar, Danish Mazhar(University of Cambridge), Hoda Abdel-Aty(MRC Clinical Trials Unit at UCL), Simon Brown, Peter Dutey‐Magni(MRC Clinical Trials Unit at UCL), Ruth E Langley(MRC Clinical Trials Unit at UCL), Jacob Tanguay, Ling Lee, Matthew Simms, Sarah Needleman, Duncan C Gilbert(MRC Clinical Trials Unit at UCL), Christopher C Parker(Royal Marsden NHS Foundation Trust), Abdel Hamid, Laura Murphy(MRC Clinical Trials Unit at UCL), Louise C Brown(MRC Clinical Trials Unit at UCL), Prantik Das, David Fackrell, Fiona Douglas, Anil Kumar, Mohammed Kagzi, Kitty Chan(MRC Clinical Trials Unit at UCL), Ursula McGovern, Mike Smith-Howell, Amit Bahl, Emilio Porfiri
Cited by 3
Related Papers
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419